Immunohistochemical expression of estrogen receptor in pulmonary adenocarcinoma

Applied Immunohistochemistry and Molecular Morphology

Volumn 14, Issue 1, 2006, Pages 83-87

  Lau, Sean K ^a   Chu, Peiguo G ^a   Weiss, Lawrence M ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Breast carcinoma; Estrogen receptor; Immunohistochemistry; Lung adenocarcinoma; Thyroid transcription factor 1

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN RECEPTOR; THYROID TRANSCRIPTION FACTOR 1;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; BRONCHUS CANCER; CELL NUCLEUS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; RECEPTORS, ESTROGEN; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 33645164823     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/01.pai.0000168593.35850.9c     Document Type: Article

References (26)

1. Hill CA, North LB, Osborne BM. Bronchogenic carcinoma in breast carcinoma patients. AJR Am J Roentgenol. 1983;140:259-264.
2. Casey JJ, Stempel BG, Scanlon EF, et al. The solitary pulmonary nodule in the patient with breast cancer. Surgery. 1984;96:801-805.
3. Raab SS, Berg LC, Swanson PE, et al. Adenocarcinoma in the lung in patients with breast cancer. A prospective analysis of the discriminatory value of immunohistology. Am J Clin Pathol. 1993;100:27-35.
4. Deamant FD, Pombo MT, Battifora H. Estrogen receptor immunohistochemistry as a predictor of site of origin in metastatic breast cancer. Appl Immunohistochem Mol Morphol. 1993;1:188-192.
5. Kaufmann O, Deidesheimer T, Muehlenberg M, et al. Immunohistochemical differentiation of metastatic breast carcinomas from metastatic adenocarcinomas of other common primary sites. Histopathology. 1996;29:233-240.
6. Lee BH, Hecht JL, Pinkus JL, et al. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. Am J Clin Pathol. 2002;117:745-750.
7. Ollayos CW, Riordan GP, Rushin JM. Estrogen receptor detection in paraffin sections of adenocarcinoma of the colon, pancreas, and lung. Arch Pathol Lab Med. 1994;118:630-632.
8. Kaiser U, Hofmann J, Schilli M, et al. Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. Int J Cancer. 1996;67:357-364.
9. Su JM, Hsu HK, Chang H, et al. Expression of estrogen and progesterone receptors in non-small-cell lung cancer: immunohistochemical study. Anticancer Res. 1996;16:3803-3806.
10. Brown RW, Campagna LB, Dunn JK, et al. Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. A diagnostic adjunct in the determination of primary site. Am J Clin Pathol. 1997;107:12-19.
11. Vargas SO, Leslie KO, Vacek PM, et al. Estrogen-receptor-related protein p29 in primary non-small cell lung carcinoma: pathologic and prognostic correlations. Cancer. 1998;82:1495-1500.
12. Kaufmann O, Kother S, Dietel M. Use of antibodies against estrogen and progesterone receptors to identify metastatic breast and ovarian carcinomas by conventional immunohistochemical and tyramide signal amplification methods. Mod Pathol. 1998;11:357-363.
13. Di Nunno L, Larsson LG, Rinehart JJ, et al. Estrogen and progesterone receptors in non-small cell lung cancer in 248 consecutive patients who underwent surgical resection. Arch Pathol Lab Med. 2000;124:1467-1470.
14. Omoto Y, Kobayashi Y, Nishida K, et al. Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. Biochem Biophys Res Commun. 2001;285:340-347.
15. Radzikowska E, Langfort R, Giedronowicz D. Estrogen and progesterone receptors in non-small cell lung cancer patients. Ann Thorac Cardiovasc Surg. 2002;8:69-73.
16. Dabbs DJ, Landreneau RJ, Liu Y, et al. Detection of estrogen receptor by immunohistochemistry in pulmonary adenocarcinoma. Ann Thorac Surg. 2002;73:403-405.
17. Ordonez NG. Thyroid transcription factor-1 is a marker of lung and thyroid carcinomas. Adv Anal Pathol. 2000;7:123-127.
18. Lau SK, Luthringer DJ, Eisen RN. Thyroid transcription factor-1: a review. Appl Immunohistochem Mol Morphol. 2002;10:97-102.
19. Bejarano PA, Baughman RP, Biddinger PW, et al. Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Mod Pathol. 1996;9:445-452.
20. Harlamert HA, Mira J, Bejarano PA, et al. Thyroid transcription factor-1 and cytokeratins 7 and 20 in pulmonary and breast carcinoma. Acta Cytol. 1998;42:1382-1388.
21. Kaufmann O, Dietel M. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology. 2000;36:8-16.
22. Reis-Filho JS, Carrilho C, Valenti C, et al. Is TTF1 a good immunohistochemical marker to distinguish primary from metastatic lung adenocarcinomas? Pathol Res Pract. 2000;196:835-840.
23. Ordonez N. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol. 2000;24:598-606.
24. Chhieng DC, Cangiarella JF, Zakowski MF, et al. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens. Cancer. 2001;93:330-336.
25. Travis WD, Colby TV, Corrin B, et al. World Health Organization International Histologic Classification of Tumors: Histologic Typing of Lung and Pleural Tumors, 3rd ed. Berlin: Springer; 1999.
26. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-410.